Tracy A Perry

US Patent:

8278272, Oct 2, 2012

Filed:

Dec 18, 2008

Appl. No.:

12/317042

Inventors:

Nigel Greig - Phoenix MD, US
Josephine Egan - Baltimore MD, US
Maire Doyle - Baltimore MD, US
Harold Holloway - Middle River MD, US
Tracy Ann Perry - Baltimore MD, US

Assignee:

The United States of America, as represented by the Secretary, Department of Health & Human Services - Washington DC

International Classification:

A61K 38/26
C07K 14/605

US Classification:

514 117, 514 177, 514 178, 514 179, 530308

Abstract:

The invention relates to novel polypeptide analogues of GLP-1 and exendin-4. The polypeptide, in a preferred embodiment, is insulinotropic and long-acting. Preferably, the polypeptide's insulinotropic effect is comparable to or exceeds the effect of an equimolar amount of GLP-1 or exendin-4. The invention also relates to a method of treating a subject with diabetes, comprising administering to the subject the polypeptide of the invention in an amount that has an insulinotropic effect. The invention also relates to methods of using GLP-1, exendin-4, and polypeptide analogues thereof for neuroprotective and neurotrophic effects.

US Patent:

20120329715, Dec 27, 2012

Filed:

Aug 24, 2012

Appl. No.:

13/594313

Inventors:

Nigel Greig - Phoenix MD, US
Josephine Egan - Baltimore MD, US
Maire Doyle - Baltimore MD, US
Harold Holloway - Middle River MD, US
Tracy Ann Perry - Baltimore MD, US

Assignee:

The Gov. of the US, as represented by the Secretary, Dept. of Health & Human Services - Bethesda MD

International Classification:

A61K 38/26
A61P 25/00
A61P 25/28

US Classification:

514 117

Abstract:

The invention relates to novel polypeptide analogues of GLP-1 and exendin-4. The polypeptide, in a preferred embodiment, is insulinotropic and long-acting. Preferably, the polypeptide's insulinotropic effect is comparable to or exceeds the effect of an equimolar amount of GLP-1 or exendin-4. The invention also relates to a method of treating a subject with diabetes, comprising administering to the subject the polypeptide of the invention in an amount that has an insulinotropic effect. The invention also relates to methods of using GLP-1, exendin-4, and polypeptide analogues thereof for neuroprotective and neurotrophic effects.

US Patent:

7576050, Aug 18, 2009

Filed:

Jul 30, 2002

Appl. No.:

10/485140

Inventors:

Nigel Greig - Phoenix MD, US
Josephine Egan - Baltimore MD, US
Maire Doyle - Baltimore MD, US
Harold Holloway - Middle River MD, US
Tracy Ann Perry - Baltimore MD, US

Assignee:

The United States of America as represented by the Department of Health and Human Services - Washington DC

International Classification:

A61K 38/26
C07K 14/605

US Classification:

514 2, 514 12, 530308, 530324

Abstract:

The invention relates to novel polypeptide analogues of GLP-1 and exendin-4. The polypeptide, in a preferred embodiment, is insulinotropic and long-acting. Preferably, the polypeptide's insulinotropic effect is comparable to or exceeds the effect of an equimolar amount of GLP-1 or exendin-4. The invention also relates to a method of treating a subject with diabetes, comprising administering to the subject the polypeptide of the invention in an amount that has an insulinotropic effect. The invention also relates to methods of using GLP-1, exendin-4, and polypeptide analogues thereof for neuroprotective and neurotrophic effects.